Patents Assigned to Genentech
  • Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
    Patent number: 7947839
    Abstract: Bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) are described. Pharmaceutical compositions comprising an effective amount of a 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders are described. Methods are described for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a 1,8 bis-naphthalimide compound.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventors: Lewis J. Gazzard, Edward HyungSuk Ha, David Y. Jackson, Joann M. Um
  • Article of manufacture
    Patent number: 7947650
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Gene disruptions, compositions and methods relating thereto
    Patent number: 7947866
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventor: Mary Jean Sparks
  • Polyelectrolyte precipitation and purification of proteins
    Patent number: 7947813
    Abstract: Methods are presented for isolating and purifying proteins by adding a polyelectrolyte to a cell culture fluid, such as a harvested cell culture fluid, and precipitating a protein-polyelectrolyte complex or a complex of impurities and the polyelectrolyte.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventors: Robert L. Fahrner, Jayme Franklin, Paul McDonald, Thanmaya Peram, Vikram Sisodiya, Corazon Victa
  • HER2 ANTIBODY COMPOSITION
    Publication number: 20110117097
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 19, 2011
    Applicant: Genentech, Inc.
    Inventors: YUNG-HSIANG KAO, Martin Vanderlaan
  • BIOLOGICAL MARKERS FOR MONITORING PATIENT RESPONSE TO VEGF ANTAGONISTS
    Publication number: 20110117083
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for monitoring the effectiveness of treatment of with VEGF antagonists. The invention also provides methods for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: August 13, 2010
    Publication date: May 19, 2011
    Applicant: Genentech, Inc.
    Inventors: Carlos Bais, Mallika Singh, Joshua Kaminker, Matthew Brauer
  • Modulators of neuronal regeneration
    Patent number: 7943329
    Abstract: The present invention provides methods and compositions related to CNS function and diseases.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: May 17, 2011
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Marc Tessier-Lavigne
  • Method of treatment using anti-factor D antibodies
    Patent number: 7943135
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: May 17, 2011
    Assignee: Genentech, Inc.
    Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
  • Compositions and Methods Relating to STOP-1
    Publication number: 20110112279
    Abstract: The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.
    Type: Application
    Filed: July 28, 2010
    Publication date: May 12, 2011
    Applicant: Genentech, Inc.
    Inventors: HEIDI ACKERLY, Avi Ashkenazi, David Eberhard, Gretchen Frantz, Dorothy French, Germaine G. Fuh, Jo-Anne S. Hongo, Chingwei V. Lee, Scot A. Marsters, Helga A. Raab, Evgeny Varfolomeev, Beni B. Wolf, Robert Maurice Pitti, Liliana Soroceanu
  • METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES
    Publication number: 20110111408
    Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.
    Type: Application
    Filed: November 5, 2010
    Publication date: May 12, 2011
    Applicant: Genentech, Inc.
    Inventors: Matthew Marrichi, Dorothea E. Reilly, Laura C. Simmons
  • METHOD OF PROMOTING DENDRITIC SPINE DENSITY
    Publication number: 20110110942
    Abstract: The invention relates to methods of increasing density of dendritic spines as a means to retain or improve cognition and to treat disorders associated with decreased dendritic spine morphology and a psychiatric disorder such as addiction and schizophrenia or a disorder associated with impaired cognition such as autism, Lett Syndrome, Tourette Syndrome, and Fragile-X Syndrome.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 12, 2011
    Applicant: GENENTECH, INC.
    Inventors: DARA KALLOP, ANATOLY NIKOLAEV, MARC TESSIER-LAVIGNE, ROBBY WEIMER
  • Multivalent Antibodies and Uses Therefor
    Publication number: 20110110852
    Abstract: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.
    Type: Application
    Filed: November 3, 2010
    Publication date: May 12, 2011
    Applicant: Genentech, Inc.
    Inventors: Kathy L. Miller, Leonard G. Presta
  • THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20110112085
    Abstract: Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: January 13, 2011
    Publication date: May 12, 2011
    Applicants: Genentech, Inc., F. Hoffmann - LA Roche AG
    Inventors: Georgette M. Castanedo, Janet L. Gunzner, Kimberly Malesky, Simon Mathieu, Alan G. Olivero, Daniel P. Sutherlin, Shumei Wang, Bing-Yan Zhu, Irina Chuckowree, Adrian Folkes, Sally Oxenford, Nan-Chi Wan
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 7939268
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: May 10, 2011
    Assignee: Genentech, Inc.
    Inventors: Gretchen Frantz, Kenneth J. Hillan, Heidi Phillips, Paul Polakis, Susan D. Spencer, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
  • APO-2 receptor polypeptides
    Patent number: 7939631
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: May 10, 2011
    Assignee: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Stra6 polypeptides
    Patent number: 7939650
    Abstract: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: May 10, 2011
    Assignee: Genentech, Inc.
    Inventors: Diane Pennica, Victoria Smith, William I. Wood
  • NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
    Publication number: 20110104170
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: December 14, 2010
    Publication date: May 5, 2011
    Applicant: Genentech, Inc.
    Inventors: Daryl T. Baldwin, Sarah C. Bodary, Andrew C. Chen, Hilary Clark, Janet K. Jackman, William I. Wood
  • ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS OF USE THEREOF
    Publication number: 20110104184
    Abstract: Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF.
    Type: Application
    Filed: December 23, 2009
    Publication date: May 5, 2011
    Applicant: GENENTECH, INC.
    Inventors: JIN-AN JIAO, HING C. WONG, JINGHAI WEN
  • Pantropic neurotrophic factors
    Patent number: 7935671
    Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: May 3, 2011
    Assignee: Genentech, Inc.
    Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
  • Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
    Patent number: 7935791
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: May 3, 2011
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou